漢康生技 - HanchorBio - 創新、卓越、高效

創新驅動生命希望照亮未來

Innovating for Life, Inspiring Hope

Our Possibility

我們的可能性

研發專案

                                                                8
                                +
                            

專利申請

                                                                100
                                +
                            

進入臨床IND階段

最快

                                                                2.3
                                年
                            

2024年的研發投資金額

                                                                7.89
                                億元
                            

FBDB™

技術平台的核心優勢

結合先天性及適應性免疫系統多管齊下攻擊腫瘤細胞
阻斷 SIRPα / CD47 訊號傳遞
阻斷 PD-1 / PD-L1訊號傳遞
改善腫瘤微環境或進一步激活巨噬細胞/T細胞

更多核心技術

News

最新消息

HanchorBio-Podcast-innovations-in immuno-oncology

Podcast節目上線《與漢康讀懂腫瘤免疫新藥的抗癌革命》Podcast Launch: Innovations in Immuno-Oncology

漢康生技推出自製 Podcast 節目《與漢康讀懂腫瘤免疫新藥的抗癌革命》，從腫瘤免疫新藥的研發邏輯、商務策略到全球授權視角，帶領聽眾深入理解創新生技的關鍵趨勢與產業價值。

3 月 11, 2026

HanchorBio-to-Speak-at-Biologics-World-Taiwan-2026

HanchorBio to Present Next-Generation Biologics Innovation at Biologics World Taiwan 2026漢康生技受邀於第13屆台灣世界生物製劑大會發表專題演講，分享次世代生物藥創新研發與CMC策略觀點

HanchorBio will participate in IMAPAC's Biologics World Taiwan 2026, taking place on March 25–26, 2026, at Hilton Taipei Sinban, Taiwan. During the event, HanchorBio’s Chairman and Chief Executive Officer, Dr. Scott Liu, and Executive Director of CMC, Dr. Vivian Kuo, will be invited as speakers. They will share insights on next-generation biologics innovation, spanning immuno-oncology, tri-specific Fc fusion protein development, and process and CMC excellence for emerging drug modalities.

3 月 11, 2026

HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress漢康生技於第11屆亞太胃食管癌大會發表 HCB101 三藥聯合療法於二線胃癌之具劑量依賴性的腫瘤反應與持續腫瘤縮小數據

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical data from its ongoing HCB101-201 Phase 1b/2a study at the 11th Asia-Pacific Gastroesophageal Cancer Congress (APGCC). The poster highlights early findings supporting dose-dependent antitumor activity of HCB101 in combination with ramucirumab and paclitaxel among patients with advanced gastric adenocarcinoma who progressed after first-line therapy.

3 月 05, 2026

HanchorBio Founder Dr. Scott Liu Invited to Moderate at BIOCHINA 2026漢康生技創辦人劉世高博士受邀出席 BIOCHINA 2026 並擔任圓桌主持人

BIOCHINA 2026（第十一屆）易貿生物產業展覽將於 2026年3月12日至3月14日在中國大陸蘇州舉行。漢康生技創辦人、董事長暨執行長劉世高博士受邀出席本屆盛會，並將擔任「抗體藥物創新開發論壇」圓桌會議主持人，同時參與專題訪談與分享，與全球產業領袖共同探討抗體藥物創新與產業合作策略。訪談主題：細分賽道聚焦——從 BD 交易看雙／多特異性抗體創新藥布局與協同合作戰略

3 月 02, 2026

HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026漢康生技於美國癌症研究協會 (AACR) 腫瘤免疫學年會發表 HCB101 單藥與聯合治療的臨床數據

HanchorBio Presents Monotherapy and Combination Clinica […]

2 月 19, 2026

HanchorBio Receives FDA Orphan Drug Designation for HCB101 in Gastric Cancer漢康廣譜抗癌新藥HCB101獲孤兒藥認定推進晚期胃癌新療法

HanchorBio Receives FDA Orphan Drug Designation for HCB […]

2 月 13, 2026

HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026漢康生技全球臨床佈局加速　2026年第一季將於多場國際年會發表口頭及壁報論文

HanchorBio announced a robust schedule of scientific presentations at major international oncology congresses throughout Q1 2026. The selection of multiple abstracts, including four high-profile oral presentations, underscores the clinical maturity and global scientific recognition of HanchorBio’s proprietary pipeline.

2 月 05, 2026

Strategic-Partnership-Between-Hanchorbio-and-WuXi-Biologics

HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline. 致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。

1 月 26, 2026